Inhibitors of Acyl-CoA

In a previous paper, we reported a novel inhibitor of acyl-CoA : cholesterol acyltransferase (ACAT), 2-bromo-N-(2, 6-diisopropylphenyl)-6, 11-dihydrodibenz[b, e]oxepin-11-carboxamide (1). In this work, we prepared both enantiomers and tested them for ability to inhibit ACAT (liver microsomes from ch...

Full description

Saved in:
Bibliographic Details
Published inChemical & pharmaceutical bulletin Vol. 44; no. 1; p. 222
Main Authors KUMAZAWA, Toshiaki, YANASE, Masashi, SHIRAKURA, Shiro, OHISHI, Eiko, YAMADA, Koji, MATSUMIYA, Shigeki, KONO, Motomichi
Format Journal Article
LanguageEnglish
Published Tokyo Japan Science and Technology Agency 01.01.1996
Online AccessGet full text

Cover

Loading…
More Information
Summary:In a previous paper, we reported a novel inhibitor of acyl-CoA : cholesterol acyltransferase (ACAT), 2-bromo-N-(2, 6-diisopropylphenyl)-6, 11-dihydrodibenz[b, e]oxepin-11-carboxamide (1). In this work, we prepared both enantiomers and tested them for ability to inhibit ACAT (liver microsomes from cholesterol-fed rabbits) in vitro and to decrease serum total cholesterol in cholesterol-fed golden hamsters in vivo. The precursor carboxylic acid 4 was optically resolved with cinchonidine. The obtained (-)- and (+)-4 were converted to (-)- and (+)-1 without racemization, respectively. The enantiomer (-)-1 showed potent ACAT inhibitory activity in vitro with an IC50 value of 8 nM and was approximately 10-fold more active than (+)-1. Furthermore, (-)-1 showed strong hypocholesterolemic activity in vivo, whereas (+)-1 was inactive.A molecular modeling study showed that the difference of ACAT inhibitory activity between the enantiomers was derived from the spatial alignment of the bromine.Compound (-)-1 was selected for further evaluation as KW-3033.
ISSN:0009-2363
1347-5223